
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPeExVRm9LaE9EZmdXQmNwZGhsNFhNcmtWUDhXQmZQaWlGTHF6T2Jvd0lROTRJQlJ1YXhEd1JCdWl3QmN2UFFiWUwydVRsS1h6c0VqMFR0ZVJ1bnR3QmkyblVSUVZZYnhZV0xraHl1TEIxMlFOdnBWMEFLM3U4QVVBOThuMlc1MlhFRmIxV3RmbnRKenhpZVJzaDJiSU9xV3hUaGNGdEJ4eG1veFdMbGhGZ1lhcV9WZkk?oc=5" target="_blank">Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>

